If over-the-counter antihistamines aren’t effective for you, your doctor may recommend H2 blockers, steroids, biologics, or ...

RAPT Therapeutics, Inc. ( NASDAQ: RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Good morning, and welcome to RAPT's conference ...

Evommune, a biotechnology company developing treatments for chronic inflammatory conditions, revealed plans to go public in a Thursday filing with the Securities and Exchange Commission. Evommune ...

Novartis has secured FDA approval for its BTK inhibitor remibrutinib (Rhapsido) for the treatment of chronic spontaneous urticaria. Remibrutinib is the sixth BTK inhibitor to market in the US, and the ...

Kashiv Biosciences has submitted its Biologics License Applications (BLA) for ADL-018 as a biosimilar to reference product XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA) The ...

Femi Aremu, PharmD, is a Drug Information Pharmacist for Red Ventures and practiced in a COVID-19 clinic for the University of Chicago Medicine. Ozempic (semaglutide) is a medicine used to manage ...

Michael Stapelberg is a specialist general practitioner with an interest in dermatology and skin cancer who works at Skin Clinic Robina on the Gold Coast, Queensland. Mike Climstein and Nedeljka Rosic ...

The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday. Indicated for adults with stubborn ...

Washington, DC, Oct. 01, 2025 (GLOBE NEWSWIRE) -- On this Urticaria Day (UDAY), the Asthma and Allergy Foundation of America (AAFA), We CU, and The Mast Cell Disease Society (TMS) aim to raise ...

(Reuters) -The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the Swiss drugmaker said on Tuesday. The twice-daily ...

Novartis has scored the FDA’s approval for a second BTK inhibitor that’s for a non-cancer indication, teeing off a potential competition with Sanofi down the line. The FDA has blessed Novartis’ ...

In summer 2019, Bob McDonough took a full stack web development coding bootcamp at the University of Pennsylvania. An English-turned-telecommunications major in college, McDonough had been working at ...